End-to-End Solutions Planned to Support Key
Customer Applications With Increased Cost Flexibility on Long-Read
Sequencing Systems
MENLO
PARK, Calif., Feb. 7, 2023
/PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of
high-quality, highly accurate sequencing solutions, today announced
the commencement of a program intended to expand Multiplexed Arrays
Sequencing (MAS-Seq) for new assays on the Sequel II/IIe and
Revio™ sequencing systems. This program builds on the
successful MAS-Seq concatenation technology launched last year that
enabled cost-effective single-cell isoform sequencing.
The MAS-Seq technology concatenates multiple shorter fragments
which are then read on the system as one long HiFi read. This
extends the effective throughput by up to 16-fold, where the
throughput increase factor is determined by the size of the short
fragment. We believe that extending MAS-Seq technology to key
applications such as bulk RNA sequencing and 16S rRNA will provide
customers with cost-effective kitted solutions and end-to-end
software.
"Since our October announcement of the first MAS-Seq based kit,
the customer demand has been extremely encouraging, to the point
that customers have been asking us to expand the technology to
their favorite application," said Christian
Henry, President and Chief Executive Officer at PacBio. "We
believe applying MAS-Seq technology to these applications will help
deepen our understanding of biology. In RNA sequencing studies, for
example, MAS-Seq will help shift the field to true transcriptomics
research. We are tremendously excited to build on the momentum of
MAS-Seq to open new opportunities in Bulk RNA-Seq and 16S rRNA
studies for our customers."
"We are excited that PacBio is addressing the unmet need for
more cost-effective full-length RNA sequencing," said Jeremy Schmutz, Ph.D., co-director of the
HudsonAlpha Genome Sequencing Center. "HudsonAlpha uses PacBio's
Iso-Seq method (full-length RNA sequencing) for improved genome
annotations and functional research. The new MAS-Seq kits for bulk
Iso-Seq, combined with the expected increase in Revio's throughput,
will enable cutting edge research in human, plant and animal
genomics."
PacBio intends to launch this first expanded series of MAS-Seq
kits in the second half of 2023. PacBio plans to share early data
and a technical overview to interested parties at this week's
Advances in Genome Biology and Technology (AGBT) General Meeting
taking place February 6-9, 2023 in
Hollywood, FL.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier
life science technology company that is designing, developing and
manufacturing advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technology under development stem from two highly
differentiated core technologies focused on accuracy, quality and
completeness which include our existing HiFi long read sequencing
and our emerging SBB™ short-read sequencing technologies. Our
products address solutions across a broad set of research
applications including human germline sequencing, plant and animal
sciences, infectious disease and microbiology, oncology, and other
emerging applications. For more information, please visit
www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use
in diagnostic procedures.
Forward-Looking Statements
This press release
contains "forward-looking statements" within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, and the
U.S. Private Securities Litigation Reform Act of 1995. All
statements other than statements of historical fact are
forward-looking statements, including statements relating to future
availability, release time-frames, uses, accuracy, advantages,
quality or performance of, or benefits or expected benefits of
using, PacBio products or technologies, including with respect to
the potential expansion of MAS-Seq technology to new assays for use
on the Sequel II/IIe and Revio systems; providing cost-effective
kitted-solutions and end-to-end software by extending the MAS-Seq
technology; plans to launch the expanded MAS-Seq kits in the second
half of 2023 and share early data and a technical overview at AGBT;
ability to open new opportunities for customers by extending the
potential breakthroughs for patients that could result from the use
of Twist Alliance panels and PacBio technology; ability of MAS-Seq
kits and Revio to enable cutting edge research in human, plant and
animal genomics collaborations to demonstrate SBB accuracy; and
other forward-looking statements. Readers are cautioned not to
place undue reliance on these forward-looking statements and any
such forward-looking statements are qualified in their entirety by
reference to the following cautionary statements. All
forward-looking statements speak only as of the date of this press
release and are based on current expectations and involve a number
of assumptions, risks and uncertainties that could cause the actual
results to differ materially from such forward-looking statements,
including, among others, challenges inherent in developing,
manufacturing, launching, marketing and selling new products, and
achieving anticipated new sales; assumptions, risks and
uncertainties related to the ability to attract new customers and
retain and grow sales from existing customers; potential product
performance and quality issues and potential delays in
commercialization timelines; rapidly changing technologies and
extensive competition in genomic sequencing that could make the
products PacBio is developing obsolete or non-competitive; supply
chain risks; successfully completing development of a product that
is not yet commercially available; customers and prospective
customers curtailing or suspending activities utilizing our
products; the impact of U.S. export restrictions on the shipment of
PacBio products to certain countries; and third-party claims
alleging infringement of patents and proprietary rights or seeking
to invalidate PacBio's patents or proprietary rights. Readers are
strongly encouraged to read the full cautionary statements
contained in PacBio's filings with the Securities and Exchange
Commission, including the risks set forth in the company's Forms
8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or
revise any forward-looking statements.
Contact:
Investors:
Todd
Friedman
ir@pacificbiosciences.com
Media:
Lizelda
Lopez
pr@pacificbiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-to-expand-mas-seq-technology-to-16s-rrna-and-bulk-rna-seq-solutions-301740173.html
SOURCE Pacific Biosciences of California, Inc.